MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejca.2025.115537

Медицинская библиотека · European journal of cancer (Oxford, England : 1990) · 2025

Phase II trial dedicated to non-selected, pretreated cutaneous angiosarcoma: Efficacy of nivolumab (AngioCheck Study).

Fujisawa Yasuhiro, Namikawa Kenjiro, Ishitsuki Shoichiro, Yoshino Koji, Isei Taiki, Kato Hiroshi, Yanagi Teruki, Yamamoto Yuki, Uchi Hiroshi, Yasuda Masahito, Maruo Kazushi, Sugihara Eiji, Otsuka Atsushi

СтатьяКлиническое исследование II фазыМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Angiosarcoma is a rare and aggressive malignancy with limited treatment options. This phase II, multicenter, open-label, single-arm study (AngioCheck) evaluated the efficacy and safety of nivolumab in patients with cutaneous angiosarcoma previously treated with taxane-based chemotherapy.

METHODS

Eligible patients had histologically confirmed cutaneous angiosarcoma, prior treatment with docetaxel or paclitaxel, and at least one measurable lesion. Patients received nivolumab 480 mg every four weeks. The primary endpoint was the centrally reviewed overall response rate (ORR). Secondary endpoints included investigator-assessed ORR, overall survival (OS), and progression-free survival (PFS). An exploratory biomarker analysis was conducted to assess tumor mutational burden (TMB).

RESULTS

Twenty-three patients were enrolled across 11 institutions in Japan. The investigator-assessed ORR was 21.7 % (5 patients with partial response [PR], while the centrally reviewed ORR was 13.0 % (3 PR; 90 % CI: 3.7-30.4), which did not meet the predefined success threshold. The median OS was 259 days (90 % CI: 188.0-387.0), and the median PFS was 59 days (90 % CI: 57-112). TMB analysis was performed in 16 patients: among TMB-high patients (n = 7), there were 0 PR and 3 stable disease (SD); among non-TMB-high patients (n = 9), 2 PR and 1 SD were observed. Although the TMB-high group had a numerically higher disease control rate (PR + SD; 42.9 % vs. 33.3 %), no significant association between TMB status and treatment response was found.

CONCLUSIONS

Nivolumab monotherapy did not achieve the predefined response rate in this cohort of pretreated cutaneous angiosarcoma patients. No correlation between TMB-high status and objective response was identified. Further investigations are needed to explore predictive biomarkers and combination strategies to improve therapeutic efficacy.

Для цитирования: Fujisawa Yasuhiro, Namikawa Kenjiro, Ishitsuki Shoichiro, Yoshino Koji, Isei Taiki, Kato Hiroshi, Yanagi Teruki, Yamamoto Yuki, Uchi Hiroshi, Yasuda Masahito, Maruo Kazushi, Sugihara Eiji, Otsuka Atsushi. Phase II trial dedicated to non-selected, pretreated cutaneous angiosarcoma: Efficacy of nivolumab (AngioCheck Study).. European journal of cancer (Oxford, England : 1990). 2025. DOI: 10.1016/j.ejca.2025.115537.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.